Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”) today announced the initiation of a phase I/IIA clinical trial for its immunotherapy vaccine (ALZN002) to treat mild to moderate dementia of the Alzheimer’s type.
Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced positive top-line results from FO2CUS, a study evaluating the efficacy and safety of vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor, in hemodialysis patients who were converted from a long-acting erythropoiesis-stimulating agent (ESA) to three times weekly oral vadadustat dosing for the maintenance treatment of anemia.
HuidaGene Therapeutics (辉大基因; HuidaGene) announces that the US. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) for HG004, HuidaGene’s lead gene replacement therapy for the treatment of inherited retinal disease caused by RPE65 mutations.
HuidaGene Receives Orphan Drug Designation for Gene Therapy of Blindness Read More »
Unos astrónomos han observado una explosión a 180 millones de años-luz de la Tierra que desafía al conocimiento científico actual sobre las explosiones naturales en el espacio, dado que esta ha sido mucho más plana de lo que hasta ahora se creía que e …
Por vez primera, se ha conseguido grabar y analizar sonidos emitidos por vegetales. Los sonidos, parecidos al estallido de las palomitas de maíz, se emiten a un volumen similar al del habla humana, pero a altas frecuencias, más allá del rango de audición del oído h …
Cytokinetics is discontinuing the Phase III COURAGE-ALS trial in amyotrophic lateral sclerosis after its candidate reldesemtiv failed a planned interim analysis, the company announced Friday.
Phase III Failure Leaves Cytokinetics with One Last Late-Stage Hopeful Read More »
En este Short conoceremos cómo ha podido descubrirse actividad volcánica actual en Venus. …
The Sino-American Pharmaceutical Professionals Association-Greater Philadelphia hosted its 21st Annual Conference at the Sheraton Valley Forge Hotel northwest of Philadelphia.
The Executive Board of the Wyss Center for Bio and Neuroengineering, a non-profit research center, is pleased to announce the appointment of Prof. Dr. med. Erwin Böttinger as its new Chief Executive Officer.
Wyss Center Geneva Appoints Erwin Böttinger as new Chief Executive Officer Read More »
GC Cell, a Korean biotech company, announced on Mar. 28th that it had held the 12th General Shareholders’ Meeting at GC Biopharma R&D Center in Yongin, Gyeonggi-do of South Korea and resolved some major agenda items, including the appointment of inside directors.
GC Cell and New Management Embarking on a New Chapter Read More »
